

METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No: 62/684,288, filed on June 13, 2018, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

10 The invention relates to new pharmaceutical compositions comprising aldesleukin/SDS aggregates stable in solution and their pharmaceutical uses

BACKGROUND

Interleukin 2 (IL-2) is a key cytokine regulating survival, proliferation and differentiation of T cells and NK cells (1). Discovery of these biological activities led to approval for clinical application of IL-2 in cancer immunotherapy for metastatic renal carcinoma in 1994 and for metastatic melanoma in 1998. Afterwards, IL-2 emerged as a reagent to drive in vitro expansion of T lymphocytes extracted from a tumor (tumor infiltrating lymphocytes, TILs) of a patient, that were then transfer back to the patient in order to avoid future cancer development (2). Recently, IL-2 has been also used to expand T cells transduced with antigen-specific T cells receptors (3), or transduced with chimeric antigen receptors (CARs) for cancer treatments (4). A new field of IL-2 medical applications recently emerged as a consequence of the discovery that IL-2 have dual functions in the immune response: a) the well-known activity as activator of the inflammatory response and b) as a down regulator of the inflammatory response inducing the expansion of T regulatory cells (CD4⁺Foxp3⁺Treg cells) (5). This seemingly paradoxical duality, can be explain by the existence of two kind of IL-2 receptors with high or low affinities and their particular cellular distribution (5). This IL-2 duality resulted in opposing therapies as follows: a) use of IL-2 in high doses to stimulate the immune response like in the original treatments of cancer, and b) use of IL-2 in low doses to depress excessive or aberrant immune response like in the treatment of autoimmune or inflammatory disorders.

30 Most (if not all) of the current clinical applications of IL-2 are carried out using a recombinant mutated version of natural IL-2 named aldesleukin (des-ala-2ser125) (PROLEUKINTM). US patent 4,604,377 teaches how to prepared a pharmaceutical

composition of recombinant IL-2 (including aldesleukin) consistent in a sterile, stable lyophilized formulation in which the recombinant IL-2 is admixed with a water soluble carrier such as mannitol that provides bulk, and sufficient amount of sodium dodecyl sulfate to ensure the solubility of the recombinant IL-2 in water. The formulation is suitable for reconstitution in aqueous injections for parenteral administration stable and well tolerated in human patients. On the other hand, a detailed description of the process by which the PROLEUKIN™ product is prepared has been more recently disclosed in the European patent EP 1,688,146 B.

SUMMARY

In one aspect, the present disclosure refers to a method of producing aldesleukin in a pharmaceutical liquid composition, the method comprising: fermenting a bacterial cell transfected with an expression vector encoding an aldesleukin gene; disrupting the bacterial cell; collecting inclusion bodies containing aldesleukin; subjecting the inclusion bodies to dissolution by a sodium dodecyl sulfate (SDS) detergent followed by oxidation and then a first chromatography; diluting with an organic nitrile and subjecting to a second chromatography; subjecting the aldesleukin to diafiltration and sterilization.

In another aspect, the present disclosure refers to a pharmaceutical liquid composition containing the aldesleukin obtained by the method of claim 1 in which the aldesleukin: a) remains stable in the pharmaceutical liquid composition for at least a year as measured by the in vitro biological activity assay, b) have a stable aldesleukin/SDS aggregate distribution in the pharmaceutical liquid composition at least for a year in the range of 4 - 18 nm range with a peak at about 8 nm as measure by dynamic light scattering, c) have a stable therapeutic activity, at least for a year in the pharmaceutical liquid composition, as measure in an animal model of human cancer and d) is adequate to amplify human regulatory T cells in a cell culture.

One example of the present disclosure is a method to prepare aldesleukin highly stable in liquid pharmaceutical compositions for parenteral administration to a patient in need of an IL-2 immunotherapy, comprising, in general, the following steps: a) Fermentation of an *E.coli* strain transfected with an expression vector engineered to highly express the aldesleukin gene, b) Bacterial disruption, c) Collection of Inclusion bodies containing aldesleukin aggregates, d) Dissolution of the aldesleukin aggregates using SDS detergent, e) Oxidation with an oxidizing compound e.g. cupric chloride, f) Ceramic hydroxyapatite chromatography, g) Dilution with an

organic nitrile, e.g. acetonitrile, h) C4 column HPLC chromatography, i) Diafiltration and j) Filter sterilization.

A second example of the present disclosure is a composition of aldesleukin in a pharmaceutical suitable aqueous vehicle, for parenteral administration to a patient in need of IL-2 immunotherapy, in which the aldesleukin has been prepared using the production method of the disclosure that ensures that the aldesleukin is stable in a pharmaceutical liquid composition for at least a year. With the composition of aldesleukin of the disclosure it is possible to prepare a pharmaceutical product consistent in one or more pre-filled syringes, each one containing a dose suitable for a given treatment, packaged in a box. This product would not need any manipulation previous to the injection into the patient, avoiding for example microbial or other possible contaminations. On the other hand, the stable liquid aldesleukin preparation of the disclosure could be advantageously introduced and homogeneously distributed in parenteral solutions commonly used in medicine for infusion, transfusion or clinical nutrition. Lately, treatments consisting in a given drug plus aldesleukin has been developed (e.g. CEPLENETM (histamine dihydrochloride) is administered in conjunction with low dose of proleukin for maintenance of first remission in patients with Acute Myeloid Leukemia). For such treatments, the stable liquid aldesleukin preparation of the disclosure may serve as the base to elaborate a unique combined preparation or a combined kit. Proleukin has been also used to induce *in vitro* proliferation of susceptible cells to be used in cell therapy procedures (5). For these procedure, the stable liquid aldesleukin of the disclosure, formulated in low concentrations, can be very advantageous in order to avoid manipulations that can result in microbial contamination and also in order to obtain a rapid and homogeneous distribution of aldesleukin in the cell culture. These are only few examples, however a person in the art, can easily imagine other applications of the stable liquid aldesleukin preparation of the disclosure.

The IL-2 molecules herein include IL-2 variants of the present disclosure comprising an amino acid sequence that has at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%

sequence identity to the IL-2 amino acid sequence (SEQ ID NO: 1). These include IL-2 variants that comprise an amino acid sequence having an N88R mutation that has at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the wild-type IL-2 amino acid sequence (i.e. SEQ ID NO: 1). Examples also include IL-2 variants that preferentially stimulate Treg cells and comprise an amino acid sequence having N88R and C125S mutations that has at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 98% sequence identity to the wild-type IL-2 amino acid sequence (SEQ ID NO: 1). Examples also include IL-2 variants that preferentially stimulate Treg cells and comprise an amino acid sequence having at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the wild-type IL-2 amino acid sequence (SEQ ID NO: 1).

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: Amino acid sequence of the recombinant human interleukin 2 (Aldesleukin) (SEQ ID NO: 1).

FIG. 2: Comparison of the aldesleukin/SDS particle size range, as measured by dynamic light scattering, between PROLEUKINTM and the aldesleukin prepared by the method of this invention.

FIG. 3: Aldesleukin/SDS particle size range of the aldesleukin prepared by the method of this invention after 0, 6 or 12 month storage at 0-8°C.

DETAILED DESCRIPTION

Embodiments of the invention are directed to a highly stable IL-2 in a liquid formulation and methods of producing the stable IL-2.

Definitions

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, and biochemistry).

As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”

The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice
5 in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value or range. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude within 5-fold, and also within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular
10 value should be assumed.

A “biological medium” as used herein, is any type of medium that is used to grow, culture and maintain organs, tissues, cells etc., *in vitro*. A biological medium also encompasses any biocompatible agent, any pharmaceutical excipient, pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions,
15 aqueous dextrose, glycerol or the like as a vehicle, tissue or organ culture media, any agent that can be administered *in vivo* to a subject, any agent that can be used in assays or for diluting or maintaining a biological sample, e.g. nucleic acids, peptides etc.

As used herein, the term “cell” includes prokaryotic and eukaryotic cells. In one embodiment, a cell of the invention is a bacterial cell. In another embodiment, a cell of the
20 invention is a fungal cell, such as a yeast cell. In another embodiment, a cell of the invention is a vertebrate cell, e.g., an avian or mammalian cell. In a preferred embodiment, a cell of the invention is a murine or human cell. As used herein, the term “engineered” (as in an engineered cell) refers to a cell into which a nucleic acid molecule e.g., encoding an IL-2 protein (e.g., a spliced and/or unspliced form of IL-2) or fragments thereof, has been
25 introduced.

As used herein, the term “cell free composition” refers to an isolated composition, which does not contain intact cells. Examples of cell free compositions include cell extracts and compositions containing isolated proteins.

As used herein, the terms “comprising,” “comprise” or “comprised,” and variations
30 thereof, in reference to defined or described elements of an item, composition, apparatus, method, process, system, etc. are meant to be inclusive or open ended, permitting additional elements, thereby indicating that the defined or described item, composition, apparatus,

method, process, system, etc. includes those specified elements--or, as appropriate, equivalents thereof--and that other elements can be included and still fall within the scope/definition of the defined item, composition, apparatus, method, process, system, etc.

The term “expression vector” refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, when the transcription product is an mRNA molecule, this is in turn translated into a protein, polypeptide, or peptide.

As used herein, the term human recombinant IL-2 (rhIL-2) is an unglycosylated protein produced by a microorganism that has been transfected with the human IL-2 codifying DNA sequence or a non-extensive modification of it. In fact, the IL-2 human recombinant version most used in clinical practices is modified version of the natural human IL-2 amino acid sequence, named aldesleukin (PROLEUKIN™) having the following modifications: a) aldesleukin has no the N-terminal alanine present in natural IL-2 b) aldesleukin has serine substituted for cysteine at amino acid position 125. Aldesleukin amino acid sequence is shown in FIG. 1. Construction of the aldesleukin gene is described in US patent 4518584A and related non-US patents. The United States FDA has approved aldesleukin (PROLEUKIN™) for use in the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma. PROLEUKIN™ is supplied as a sterile, white to off-white, lyophilized cake in 20 single-use vials intended for intravenous administration. When reconstituted with 1.2 mL Sterile water for Injection, USP, each mL contains 18 million International Units (1.1 mg) PROLEUKIN™, 50 mg mannitol, and 0.18 mg sodium dodecyl sulfate, buffered with approximately 0.17 mg monobasic and 0.89 mg dibasic sodium phosphate to a pH of 7.5 (range 7.2 to 7.8). Reconstituted or diluted PROLEUKIN™ is stable for up to 48 hours at refrigerated and room temperatures, 2° to 25°C (36° to 77°F) as stated in the Reconstitution and Dilution Directions of the “PROLEUKIN™ (aldesleukin) injection label – FDA” (Reference ID: 3165255).

As used herein, the term “interleukin 2” (IL-2) denotes a cytokine that regulates the activities of white blood cells (mainly lymphocytes). This cytokine is part of the immune response to microbial infections and exercise its effects by binding to specific receptors present on the surface of lymphocytes. Further information about IL-2 can be found in its “GeneCard” (accession number GC04M123831). Other accession numbers include: HGNC: 6001 Entrez Gene: 3558 Ensembl: ENSG00000109471 OMIM: 147680 UniProtKB: P60568.

IL-2 proteins include native IL-2 proteins, as well as variant IL-2 proteins. A "native" or "wild type" IL-2 sequence, as used herein, refers to a human IL-2 sequence (e.g., Accession No. NP 000577.2), whether purified from natural sources or made using recombinant techniques. In some embodiments, a wild type IL-2 sequence includes the PROLEUKIN™

5 (aldesleukin) sequence: (SEQ ID NO: 1)

PTSSSTKKTQLQLEHLLLDLQMLNGINNYKNPKLTRMLTFKFYMPKKAT
ELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSET
TFMCEYADETATIVEFLNRWITFAQSIISTLT

As used herein, the term "kit" refers to any delivery system for delivering materials.

10 Inclusive of the term "kits" are kits for both research and clinical applications. In the context of reaction assays, such delivery systems include systems that allow for the storage, transport, or delivery of reaction reagents (e.g., cytokines, oligonucleotides, enzymes, etc. in the appropriate containers) and/or supporting materials (e.g., buffers, written instructions for performing the assay etc.) from one location to another. For example, kits include one or

15 more enclosures (e.g., boxes) containing the relevant reaction reagents and/or supporting materials. As used herein, the term "fragmented kit" refers to delivery systems comprising two or more separate containers that each contains a subportion of the total kit components. The containers may be delivered to the intended recipient together or separately. For example, a first container may contain an enzyme for use in an assay, while a second

20 container contains oligonucleotides or liposomes. The term "fragmented kit" is intended to encompass kits containing Analyte specific reagents (ASR's) regulated under section 520(e) of the Federal Food, Drug, and Cosmetic Act, but are not limited thereto. Indeed, any delivery system comprising two or more separate containers that each contains a subportion of the total kit components are included in the term "fragmented kit." In contrast, a

25 "combined kit" refers to a delivery system containing all of the components of a reaction assay in a single container (e.g., in a single box housing each of the desired components). The term "kit" includes both fragmented and combined kits.

As used in this specification and the appended claims, the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.

30 The phrase "pharmaceutically acceptable carrier" refers to a carrier for the administration of a therapeutic agent. Exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically

acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

As used herein, “stable” or “highly stable” refers to the activity and/or the integrity of the molecule, e.g. IL-2, in the formulations embodied herein, over extended periods of time, as evaluated by biological activity *in vitro*, structural studies *in vitro* and therapeutic activity *in vivo*. The activity of the IL-2 can be measured by any standard assay. The activity before storage and after long-term storage, e.g. at least one year, can be compared. Highly stable IL-2 would have the same or slightly less activity as compared to the activity at the time of IL-2 when first formulated.

Genbank and NCBI submissions indicated by accession number cited herein are incorporated herein by reference. All other published references, documents, manuscripts and scientific literature cited herein are incorporated herein by reference. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

Methods of Producing Stable IL-2 Formulations

The invention is based in part on a novel method for preparing aldesleukin, which results in a product fulfilling all the structural and biological characteristics of

PROLEUKIN™ but that surprisingly is very stable (at least one year) in solution as evaluated by biological activity “*in vitro*”, structural studies “*in vitro*” and therapeutic activity “*in vivo*”. An exemplary method to prepare aldesleukin largely stable in solution comprises the following steps:

- 5 a) Fermentation of an *E. coli* strain transfected with an expression vector engineered to highly express the aldesleukin gene. Bacteria are preferred microorganisms for producing IL-2 and among bacteria *E. coli* strains are the most preferred. *Escherichia coli* B serves as a research model and also for protein expression in life science laboratories and in the biotech industry. Characteristics such as protease deficiency, low acetate production at a high level of glucose, and enhanced permeability (probably due to a simple cell surface) make *E. coli* B a
- 10 desirable host for the production of genetically engineered proteins. Differences between B strains and K12 include the absence of flagellar component genes, the DNA cytosine methylase dcm, and ompT in BL21(DE3). B strains may have an additional type II secretion system not found in K12. BL21(DE3) also carries a DE3 recombinant phage harboring the T7
- 15 RNA polymerase gene that can direct high-level expression of cloned genes under the control of the T7 promoter. Typical *E. coli* strains used for recombinant protein expression are: BL21 (a B *E. coli* strain that protects target protein from lon and ompT proteases) and their derivatives such as: Lysogenic DE3 (based on T7 polymerase), pLysS, pLysE (express T7 lysozyme reducing basal expression of target genes), Origami (allows disulfide bond
- 20 formation in *E. coli* cytoplasm), Rosetta (enhances expression of proteins that contain codons rarely used in *E. coli*). Similar versions exist under the K12 *E. coli* genetic background. Typical plasmid vectors for high expression of recombinant proteins in *E. coli* are: pET series based on pBR322 origin and T7/lac promoters; pBad with araBAD promoter and pUC origin; pGEX with tac promoter and pBR322 origin also. Combination of fusion tags sequences,
- 25 protease cleavage sites, selection markers and strain compatibility are source for the most usual list of high expression plasmid variants.

Expression vectors are commercially available and a DNA sequence coding for the aldesleukin amino-acid sequence is inserted into the vector. The cells used in the instant assays can be eukaryotic or prokaryotic in origin. For example, in one embodiment, the cell is

30 a bacterial cell. In another embodiment, the cell is a fungal cell, e.g., a yeast cell. In another embodiment, the cell is a vertebrate cell, e.g., an avian or a mammalian cell. In another embodiment, the cell is a human cell. The cells of the invention can express endogenous IL-2 or fragments thereof, or can be engineered to do so. For example, a cell that has been

engineered to express the IL-2 or fragments thereof can be produced by introducing into the cell an expression vector encoding the protein.

In certain embodiments, the cell is an *E. coli* cell. Different *E. coli* strains can be transfected in order to obtain optimal aldesleukin production.

5 a) Aldesleukin producing bacteria can be cultured in a suitable growth medium. For example, the medium may contain each 9 liters, 216 gr of Yeast Extract, 108 gr of Soy Peptone, 113 of gr K₂HPO₄, 20,8 gr KH₂PO₄, 36 ml of Glycerol and 4 ml of Antifoam (2% v/v). Fermentation conditions may be: Temperature: 37°C ± 0.5°C, agitation: 350 rpm ± 10 rpm, air flow: 9 L/min ± 1 L/min, pO₂: set point 40%, agitation cascade: between 21% and 10 36% running between 350 rpm and 440 rpm, pH between 6.95 and 7.5 and inlet air pressure at 2 bar before starting Oxygen flow. After this, a feeding procedure should be followed. For example, feeding with a glucose solution 40% p/v by drip, to maintain a concentration of 0.1 %. Once the OD₆₀₀ reaches 5 to 10, an appropriated inducer such as Isopropil-β-D-1-tiogalactopiranósido (IPTG) should be added to reach an operative concentration. At this 15 point, the feeding with Glucose may be reduced to keep a glucose concentration of about 0.01%. Fermentation can be stop usually about 18 to 24 hours after inoculation. After fermentation, bacteria can be concentrated 5 to 7 times by centrifugation or tangential filtration and processed immediately or preserved at 2-8 °C (no more than 24 hours) or preserved at -20°C (for more than 24 hours).

20 b) After culture, aldesleukin is inside the bacteria, predominantly in the form aggregates named inclusion bodies (Ib). These Ib can be isolated by disruption of bacteria (for example by sonication). For this, bacteria could be suspended in purified water at temperature between 17 and 22°C before starting the disruption process. After this, the suspension could be circulated 2-3 times for the disruptor at a pressure of about 1400 bar. 25 The lysate should be processed immediately or preserved at -20°C. The Ib are separated of other components of the lysate by centrifugation or tangential filtration and washed. The final buffer for the Ib washing may be TE (10 mM Tris-HCl, 1 mM disodium EDTA, pH 8.0). The Ib preparation should be stored at -20°C until further processing. The Ib are then suspended in a buffer containing 10 mM sodium Phosphate, 1% SDS, pH8.0 and stirred for 1hour. Then, 30 an oxidation solution of cupric chloride is added to reach 100 μM final concentration and stirring should continue for 2 more hours. After this EDTA should be add to reach a 100 μM final concentration. The Mixture should be store at 2-8 °C until used in the downstream process.

c) The first chromatography is carried out using a ceramic hydroxyapatite (Type I 80 µm Bio-Rad) column. The aldesleukin preparation is loaded, washed with a solution 100 mM sodium phosphate, 0.3% SDS, pH 6.5 and eluted with a solution 250 mM sodium phosphate, 0.3% , pH 6.5.

5 d) The second chromatography is carried out using an HPLC C4 column. The solution containing the aldesleukin recovered from the first chromatography is mixed with acetonitrile (9 parts of the chromatography I pool elution and one part of Acetonitrile). After loaded aldesleukin is eluted using a gradient of Acetonitrile. Fractions containing aldesleukin are collected in a solution containing 73 mM sodium phosphate, 0.3 % SDS, pH 7.4.

10 e) The last step in aldesleukin purification is a diafiltration using 5kD cassettes. Aldesleukin is equilibrated using a buffer containing 0.44 mg/ml SDS, 50 mg/ml mannitol, 1.19 mg/ml disodium phosphate, 0.26 mg/ml monosodium di-hydrated phosphate, pH 7.5.

Surprisingly it was found that the aldesleukin/SDS complexes obtained by the production method of the invention do not need to be lyophilized as described in EP 1 688
15 146 B1. In order to be stabilized, since they are stable in solution for at least one year as described in examples 4 and 6.

According to the dynamic light scattering assays shown in examples 3 and 4, the aldesleukin/SDS aggregates obtained by the production method of the invention have an extended size range between 4 and 18 nm with a peak at about 8 nm. Even though
20 reconstituted PROLEUKINTM also shows a similar distribution curve, the area under this curve is clearly lower than the area under the curve of the aldesleukin/SDS particles prepared by the method of the invention. Since the protein mass used in both cases is the same, this result suggest that upon reconstitution, part of the PROLEUKINTM may remain as large aggregates. In fact, in order to measure the full activity of PROLEUKINTM, it has been
25 reported that the lyophilized preparation should be suspended in an SDS solution to avoid aggregate formation (6).

WO 2017068031 A1 describes a liquid pharmaceutical composition suitable for injection to a patient, consisting essentially of interleukin-2 at a concentration of 0.1 to 20 million IU/mL can be obtained. This composition, in order to maintain stability in solution
30 the interleukin 2 should contain an anionic surfactant, such as sodium dodecyl sulfate (SDS) that may be present at a concentration of about 0.05 to 0.5 mg/ml. However, addition of SDS in solution forms biologically active microaggregates with IL-2, as seen in the

PROLEUKIN™ product and that the microaggregation state of IL-2 is important for the therapeutic efficacy (EP 1 688 146 B1). Therefore, the microaggregation state and the therapeutic value of any novel IL-2 composition should be assessed. Regarding this, Examples 3 and 4 show the microaggregation state and stability and Example 6 an assay to
5 assess the therapeutic value of the aldesleukin/SDS aggregates obtained by the method of the invention.

The following examples further illustrates the invention. These examples are not intended to limit the invention in any manner.

EXAMPLES

10 EXAMPLE 1: *Amino acid sequence of the aldesleukin obtained by the production method of the invention.*

The amino acid sequence of the aldesleukin obtained by the production method of the invention was deduced by DNA sequencing of the aldesleukin gene present in the expression plasmid used in the method. FIG. 1 shows the obtained amino acid sequence.

15 EXAMPLE 2: *Specific activity of the aldesleukin/SDS aggregates obtained by the production method of the invention.*

The biological activity of the aldesleukin/SDS aggregates obtained by the production method of the invention was determined by the proliferation of the HT-2 cell line assay. The specific activity of 20 independent lots was in the range of 16.6 – 19,5 IU/mg calibrated with
20 the WHO International Standard for INTERLEUKIN 2 (Human, rDNA derived) NIBSC code: 86/500. This range of specific activity is similar to the declared specific activity of the aldesleukin/SDS aggregates prepared according to EP 1 688 146 B1.

25 EXAMPLE 3: *Comparative size, measured by dynamic light scattering, of the SDS/Proleukin aggregates obtained after reconstitution from the lyophilized commercial preparation and the SDS/aldesleukin aggregates obtained using the method of the invention.*

Dynamic light scattering was used to determine the size and polydispersity of the aldesleukin/SDS aggregates using a Zetasizer Nano ZS and the Zeta Nano Series software (Malvern Instruments, Germany). 100 µL sample was diluted in 1 mL pure water and measured at 25 °C five times for 30 sec with 30 sec equilibration time between
30 measurements. Particle size is expressed as the hydrodynamic diameter in nm. FIG. 2 shows dynamic light scattering patterns for the SDS/aldesleukin aggregates obtained using the

method of the invention and for PROLEUKIN™ after reconstitution from the lyophilized commercial preparation. The aldesleukin/SDS aggregates obtained by the production method of the invention display an extended size range between 4 and 18 nm with a peak at about 8 nm. PROLEUKIN™ also shows a similar distribution curve. However, the area under this curve is clearly lower than the area under the curve of the aldesleukin/SDS particles prepared by the method of the invention. Since the protein mass used in both analyzed samples was the same, this result suggests that upon reconstitution, part of the PROLEUKIN™ may remain as large aggregates not amenable to be studied with the used technique.

EXAMPLE 4: Stability of the SDS/aldesleukin preparation of the aldesleukin obtained by the production method of the invention

Table 1 shows the activity changes in specific activity with the storage time at 2-8 °C. Besides the specific activity, in each sample the following characteristics were assayed: visual observation for anomalies, pH, volume, Western Blot, SDS PAGE (reducing and non-reducing conditions), Lowry, endotoxin contamination (LAL test) and sterility. At all measured times, these assays resulted normal.

TABLE 1: *Specific activity of the soluble aldesleukin/SDS aggregates obtained by the method of this invention*

Time (months)	0	3	6	9	12
Specific activity (IU/mg)	18.8	17.1	16.5	16.9	17.4

Furthermore, FIG. 3 shows that the size distribution of the aldesleukin/SDS aggregates, as measured by dynamic light scattering, is well preserved in the aldesleukin liquid composition of the invention after 6 or 12 months storage at 2-8 °C.

EXAMPLE 5: *Regulatory T cells (Treg) expansion in human peripheral mononuclear blood cells (PMBC) incubated with the SDS/aldesleukin aggregates obtained by the production method of the invention*

Treg cells were recovered from human PMBC using the DYNABEADS™ Regulatory CD4⁺/CD25⁺ T Cell Kit (ThermoFisher Scientific). Aldesleukin/SDS aggregates capacity to induce Treg proliferation was evaluated using the CD3/CD28 DYNABEADS® Human Treg Expander ((ThermoFisher Scientific) protocol. 500IU of the aldesleukin preparations were used for Treg expansion. After 7 days expansion Tregs were counted. Expansion was 76-125

times for both, the aldesleukin/SDS aggregates obtained using the method of the invention or the method fully disclosed in EP1 688 146 B1.

EXAMPLE 6: *Therapeutic activity of the aldesleukin/SDS aggregates obtained using the production method of the invention*

5 A pulmonary metastasis model using B16F10 tumor cells as described (7), was used in order to compare the therapeutic efficiency of the aggregates of aldesleukin prepared by the method of this invention and the aldesleukin/SDS aggregates of PROLEUKIN™. Eight week old female C57BL/6 mice were intravenously injected into the tail vein with 0.5 ml of a cell suspension containing 2×10^5 B16 cells. After this, mice were separated in three groups
10 of ten mice each. Group 1 mice received a 7.0 mg/Kg dose of PROLEUKIN™, daily from days 3 to 10. Group 2 mice received a 7.0 mg/Kg dose of the micro-aggregates of aldesleukin prepared by the method of this invention, daily from days 3 to 10. Group 3 mice received vehicle daily from days 3 to 10. Mice were euthanized on day 16 after tumor inoculation and lung metastases counted as described (7). Table 2 shows that the median number of
15 metastases observed with the micro-aggregates prepared by the method of this invention was 4.3 (range 1-12), compared to 5.5 (range 3-22) with PROLEUKIN™, being this difference not significant.

TABLE 2: *Therapeutic activity of the aldesleukin/SDS aggregates obtained using the production method of the invention*

20	Treatment	metastases (mean)	range
	Vehicle	137.6	39-280
	PROLEUKIN™	5.5	3-22
25	Aldesleukin (Aggregates of the invention)	4.3	1-12

The aldesleukin prepared by the method of this invention and used in this assay was freshly produced. In contrast, Table 3 shows the same assay performed with the aldesleukin prepared by the method of this invention after storage for 6 or 12 months at 2-8 °C.

TABLE 3: Therapeutic activity of the aldesleukin/SDS aggregates obtained using the production method of the invention after 6 or 12 months of storage at 2-8 °C for 6 or 12 months. These results reinforce the idea that the liquid preparation of aldesleukin obtained by the method of the invention, is stable for at least a year.

	Treatment	metastases (mean)	range
	Vehicle	182	24-332
10	6 month storage		
	Aldesleukin (Aggregates of the invention) 6 month storage	8,4	0-35
15	Vehicle	123.2	12-156
	12 month storage		
	Aldesleukin (Aggregates of the invention) 12 month storage	3.7	1-27
20			

SEQUENCES

SEQ ID NO: 1

LENGTH: 132

25 PRT

ORGANISM: Artificial Sequence, mature des-alanyl-1 serine 125 variant of human interleukin-2

Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln
Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys
30 Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu

Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr
 Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile
 Ser Thr Leu Thr

5

References

US PATENT DOCUMENTS

US 4,604,377 Aug. 5, 1986

OTHER PATENT DOCUMENTS

EP 1 688 146 B1 18.07.2007

10 WO 2 017 068 031 A1 Abr. 27, 2017

OTHER PUBLICATIONS

1- Malek TR. The biology of interleukin-2. Annu Rev Immunol. (2008). 26:453-579.
 DOI: 10.1146/annurev.immunol.26.021607.090357

2- Dudley ME et al. Adoptive Cell Transfer Therapy Following NonMyeloablative but
 15 Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic
 Melanoma. Journal of Clinical Oncology. (2005). 23: 2346-57. DOI:
 10.1200/JCO.2005.00.240

3- Langerman A, Callender GG, Nishimura MI. Retroviral transduction of peptide
 stimulated t cells can generate dual t cell receptor-expressing (bifunctional) t cells reactive
 20 with two defined antigens. Journal of Translational Medicine. (2004). 2:4-8. DOI:
 10.1186/1479-5876-2-42

4- Magee MS, Snook AE. Challenges to chimeric antigen receptor (CAR)-T cell therapy
 for cancer. Discov Med. (2014). 18:265-71

5- Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: Biology, Design and
 25 Application. Trends Immunol. (2015). 36:763-777. DOI: 10.1016/j.it.2015.10.003

6- Hank JA, Surfus J, Gan , Albertini M, Lindstrom M, Schiller JH, Hotton KM,
 Khorsand M, Sondel PM. Distinct clinical and laboratory activity of two recombinant
 interleukin-2 preparations. Clin Cancer Res. 1999 5:281-9

7- Overwijk WW, Restifo NP. B16 as a Mouse Model for Human Melanoma. Curr Protoc Immunol. (2001). CHAPTER: Unit-20.1.

What is claimed:

1. A method of producing aldesleukin in a pharmaceutical liquid composition, the method comprising:

fermenting a bacterial cell transfected with an expression vector encoding an aldesleukin gene;

disrupting the bacterial cell;

collecting inclusion bodies containing aldesleukin;

subjecting the inclusion bodies to dissolution by a sodium dodecyl sulfate (SDS) detergent followed by oxidation and then a first chromatography;

diluting with an organic nitrile and subjecting to a second chromatography;

subjecting the aldesleukin to diafiltration and sterilization.

2. The method of claim 1, wherein the bacterial cell is an *Escherichia coli* bacterial cell.

3. The method of claim 1, wherein the oxidation is conducted with an oxidizing compound.

4. The method of claim 1, wherein the first chromatography is a ceramic hydroxyapatite chromatography.

5. The method of claim 1, wherein the second chromatography is a high-performance liquid chromatography (HPLC).

6. The method of claim 5, wherein the HPLC is C4 column HPLC chromatography.

7. The method of claim 1, wherein the aldesleukin remains stable in the pharmaceutical liquid composition for at least a year as measured by an *in vitro* biological activity assay.

8. The method of claim 1, wherein the aldesleukin comprises a stable aldesleukin/SDS aggregate distribution in the pharmaceutical liquid composition at least for a year in a range of 4 - 18 nm with a peak at about 8 nm as measured by dynamic light scattering.

9. The method of claim 1, wherein the aldesleukin has a stable therapeutic activity, at least for a year in the pharmaceutical liquid composition, as measured in an animal model of human cancer.

10. The method of claim 1, wherein the aldesleukin induces proliferation of human regulatory T cells in cell culture.

11. A pharmaceutical liquid composition containing the aldesleukin obtained by the method of claim 1 in which the aldesleukin: a) remains stable in the pharmaceutical liquid composition for at least a year as measured by the in vitro biological activity assay, b) have a stable aldesleukin/SDS aggregate distribution in the pharmaceutical liquid composition at least for a year in the range of 4 - 18 nm range with a peak at about 8 nm as measure by dynamic light scattering, c) have a stable therapeutic activity, at least for a year in the pharmaceutical liquid composition, as measure in an animal model of human cancer and d) is adequate to amplify human regulatory T cells in a cell culture.